More Galleries
5 startups that are reimagining the world Bricks that grow from microorganisms, household garbage turned into art, three-wheeled bike-cars -- these startups are redefining urban living. More
Blue collar entrepreneurs These five entrepreneurs took their blue collar experience and used it to launch innovative businesses. More
7 lifehacks to eliminate your holiday hassle Whether curating the perfect gift or finding a pet-sitter, these startups offer time-saving services that might just seem like holiday magic. More

Special Offer
22 of 36
Bringing TB diagnosis into the 21st century
Bringing TB diagnosis into the 21st century
John Agerholm, Martin Klint Hansen and Ninad Gujar
Team name: Immutell

School name: University of Aarhus, Aarhus School of Business, Denmark

Team members: Jesper Eugen Olsen, John Agerholm, Martin Klint Hansen, Morten Ruhwald, Ninad Gujar, Pernille Ravn

Concept: Tuberculosis remains a global epidemic. Most hospitals and healthcare facilities use the century-old Tuberculin Skin Test to diagnose the disease. Using its new Cell Mediated Immune Response technology, Immutell hopes to bring TB testing into the twenty-first century.

Immutell plans to first create a blood test for the IP-10 biomarker, a molecule created by TB antigens. Its method promises to detect the marker more accurately and less expensively than today's methods. If successful, the technique could eventually be used to diagnose other infectious diseases such as chlamydia, gonorrhea and malaria.Immutell's team members hail from the worlds of finance, management, engineering, and science, and bring a combined 50 years of experience to the project. The company hopes to launch its product first in the European market and then bring it to the United States.

Timeline: Assuming FDA approval in 2008, Immutell's product should be on the European market in 2009 and in the U.S. by mid-2010. - Jennifer Lawinski

NEXT: RFID tags for hospitals

Last updated May 02 2008: 11:51 AM ET